Background Obesity pharmacotherapy strategies differ in maintenance dose, titration, and lifestyle support, but existing syntheses primarily compare drugs rather than treatment-initiation decisions. We assessed 1-year weight reduction, permanent discontinuation, and incremental dose-related trade-offs while mapping the availability of eligible trial evidence. Methods We searched eight databases and two trial registries through October 2026 for randomised trials (at least 12 weeks) of obesity pharmacotherapy initiation in adults with overweight or obesity.
Evidence availability for 1-year obesity treatment-initiation decisions: an estimand-aligned Bayesian longitudinal network meta-analysis
calendar_today
November 13, 2026
person
Yin, X., Dai, M., Xia, Z., Liu, D., Huang, G., Li, X., Wang, X.
domain
medrxiv